CR Pharmaceutical (3320) Announces CR Sanjiu’s 2025 Preliminary Financial Results

Bulletin Express

Feb 06

China Resources Pharmaceutical Group Limited (HKEX: 3320) reported that its subsidiary, China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (CR Sanjiu), released unaudited preliminary financial data for the year ended 31 December 2025. CR Sanjiu is 63.22% indirectly owned by China Resources Pharmaceutical Group.

According to the announcement, CR Sanjiu recorded total operating revenue of RMB31.629 billion, marking a 14.53% year-on-year increase. Net profit attributable to shareholders reached RMB3.422 billion, up 1.60% year-on-year. At the end of 2025, total assets rose to RMB58.807 billion, largely attributed to the acquisition of Tasly Pharmaceutical Group Co., Ltd. during the reporting period. Share capital expanded by 29.58% compared to the beginning of the period, and net assets per share attributable to shareholders declined by 14.06% to RMB13.32 due to the higher share base.

The aforementioned figures are based on unaudited financial statements prepared under PRC Generally Accepted Accounting Principles. Final audited results will be disclosed in CR Sanjiu’s 2025 annual report. The information pertains solely to CR Sanjiu and does not offer a comprehensive picture of the overall operations or financial condition of the broader group. Shareholders and potential investors are advised to exercise caution when interpreting these data points.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1134027492"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1134027492\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1134027492?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-06 20:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1134027492","market":"hk","top_or_hot":-1,"title":"CR Pharmaceutical (3320) Announces CR Sanjiu’s 2025 Preliminary Financial Results","media":"Bulletin Express","content":"<p>China Resources Pharmaceutical Group Limited (HKEX: 3320) reported that its subsidiary, China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (CR Sanjiu), released unaudited preliminary financial data for the year ended 31 December 2025. CR Sanjiu is 63.22% indirectly owned by China Resources Pharmaceutical Group.</p>\n<p>According to the announcement, CR Sanjiu recorded total operating revenue of RMB31.629 billion, marking a 14.53% year-on-year increase. Net profit attributable to shareholders reached RMB3.422 billion, up 1.60% year-on-year. At the end of 2025, total assets rose to RMB58.807 billion, largely attributed to the acquisition of Tasly Pharmaceutical Group Co., Ltd. during the reporting period. Share capital expanded by 29.58% compared to the beginning of the period, and net assets per share attributable to shareholders declined by 14.06% to RMB13.32 due to the higher share base.</p>\n<p>The aforementioned figures are based on unaudited financial statements prepared under PRC Generally Accepted Accounting Principles. Final audited results will be disclosed in CR Sanjiu’s 2025 annual report. The information pertains solely to CR Sanjiu and does not offer a comprehensive picture of the overall operations or financial condition of the broader group. Shareholders and potential investors are advised to exercise caution when interpreting these data points.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CR Pharmaceutical (3320) Announces CR Sanjiu’s 2025 Preliminary Financial Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCR Pharmaceutical (3320) Announces CR Sanjiu’s 2025 Preliminary Financial Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-02-06 20:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>China Resources Pharmaceutical Group Limited (HKEX: 3320) reported that its subsidiary, China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (CR Sanjiu), released unaudited preliminary financial data for the year ended 31 December 2025. CR Sanjiu is 63.22% indirectly owned by China Resources Pharmaceutical Group.</p>\n<p>According to the announcement, CR Sanjiu recorded total operating revenue of RMB31.629 billion, marking a 14.53% year-on-year increase. Net profit attributable to shareholders reached RMB3.422 billion, up 1.60% year-on-year. At the end of 2025, total assets rose to RMB58.807 billion, largely attributed to the acquisition of Tasly Pharmaceutical Group Co., Ltd. during the reporting period. Share capital expanded by 29.58% compared to the beginning of the period, and net assets per share attributable to shareholders declined by 14.06% to RMB13.32 due to the higher share base.</p>\n<p>The aforementioned figures are based on unaudited financial statements prepared under PRC Generally Accepted Accounting Principles. Final audited results will be disclosed in CR Sanjiu’s 2025 annual report. The information pertains solely to CR Sanjiu and does not offer a comprehensive picture of the overall operations or financial condition of the broader group. Shareholders and potential investors are advised to exercise caution when interpreting these data points.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03320","symbol_name":"华润医药","start_time":0,"source_url":"","article_id":"1134027492","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1134027492","pubTimestamp":1770381765,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"China Resources Pharmaceutical Group Limited (HKEX: 3320) reported that its subsidiary, China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (CR Sanjiu), released unaudited preliminary financial...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03320":"华润医药"},"translate_title":"华润医药(3320)公布华润三九2025年初步财务业绩","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03320":1},"content_text":"China Resources Pharmaceutical Group Limited (HKEX: 3320) reported that its subsidiary, China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (CR Sanjiu), released unaudited preliminary financial data for the year ended 31 December 2025. CR Sanjiu is 63.22% indirectly owned by China Resources Pharmaceutical Group.\nAccording to the announcement, CR Sanjiu recorded total operating revenue of RMB31.629 billion, marking a 14.53% year-on-year increase. Net profit attributable to shareholders reached RMB3.422 billion, up 1.60% year-on-year. At the end of 2025, total assets rose to RMB58.807 billion, largely attributed to the acquisition of Tasly Pharmaceutical Group Co., Ltd. during the reporting period. Share capital expanded by 29.58% compared to the beginning of the period, and net assets per share attributable to shareholders declined by 14.06% to RMB13.32 due to the higher share base.\nThe aforementioned figures are based on unaudited financial statements prepared under PRC Generally Accepted Accounting Principles. Final audited results will be disclosed in CR Sanjiu’s 2025 annual report. The information pertains solely to CR Sanjiu and does not offer a comprehensive picture of the overall operations or financial condition of the broader group. Shareholders and potential investors are advised to exercise caution when interpreting these data points.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}